{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasma+Exchange+and+IVIG+%28Intravenous+Immunoglobulin+%29",
    "query": {
      "intervention": "Plasma Exchange and IVIG (Intravenous Immunoglobulin )"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Plasma+Exchange+and+IVIG+%28Intravenous+Immunoglobulin+%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T07:42:41.787Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05156710",
      "title": "BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "BIVV020 (SAR445088)",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulin (IVIg)",
          "type": "DRUG"
        },
        {
          "name": "Rituximab or biosimilar",
          "type": "DRUG"
        },
        {
          "name": "Antithymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2022-06-09",
      "completion_date": "2026-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05156710"
    },
    {
      "nct_id": "NCT01561053",
      "title": "A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Albumin 5%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Albumin 20%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunoglobulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Instituto Grifols, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 347,
      "start_date": "2012-04-19",
      "completion_date": "2018-03-06",
      "has_results": true,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 22,
      "location_summary": "Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561053"
    },
    {
      "nct_id": "NCT02474927",
      "title": "Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John F. McDyer, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2015-11-01",
      "completion_date": "2021-07-26",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02474927"
    },
    {
      "nct_id": "NCT03772717",
      "title": "Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Non-invasive vagus nerve stimulation (nVNS)",
          "type": "DEVICE"
        },
        {
          "name": "Standard of care treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "5 Years to 21 Years"
      },
      "enrollment_count": 2,
      "start_date": "2022-02-22",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-07-14",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03772717"
    },
    {
      "nct_id": "NCT01895127",
      "title": "Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antibody-mediated Rejection",
        "Humoral Rejection"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Immunoglobulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasmapheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2013-11",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-09-21",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01895127"
    },
    {
      "nct_id": "NCT04935177",
      "title": "Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplantation in Highly Sensitized Patients"
      ],
      "interventions": [
        {
          "name": "Imlifidase",
          "type": "DRUG"
        },
        {
          "name": "PLEX",
          "type": "PROCEDURE"
        },
        {
          "name": "IVIg",
          "type": "DRUG"
        },
        {
          "name": "Anti-CD20 antibodies",
          "type": "DRUG"
        },
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Remain on wait list",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Hansa Biopharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 64,
      "start_date": "2021-10-14",
      "completion_date": "2025-06-20",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04935177"
    },
    {
      "nct_id": "NCT03380936",
      "title": "Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]",
          "type": "DRUG"
        },
        {
          "name": "Plasma Exchange and IVIG (Intravenous Immunoglobulin )",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 4,
      "start_date": "2018-01-17",
      "completion_date": "2019-10-16",
      "has_results": false,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380936"
    },
    {
      "nct_id": "NCT00230035",
      "title": "Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Autologous CD34+HPC transplantation (HSCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Plasmapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Rabbit anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Growth colony stimulating factor (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2005-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-01",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Manhassat",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00230035"
    },
    {
      "nct_id": "NCT01399593",
      "title": "Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antibody Mediated Rejection"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2011-11-02",
      "completion_date": "2015-11-13",
      "has_results": true,
      "last_update_posted_date": "2017-10-03",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01399593"
    },
    {
      "nct_id": "NCT02130817",
      "title": "Belatacept in Kidney Transplantation of Moderately Sensitized Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Antibody Mediated Rejection"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus withdrawal",
          "type": "DRUG"
        },
        {
          "name": "Plasmapheresis/Intravenous Immunoglobulin G",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymoglobulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Myfortic",
          "type": "DRUG"
        },
        {
          "name": "Steroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-09-24",
      "completion_date": "2015-10-09",
      "has_results": false,
      "last_update_posted_date": "2018-12-17",
      "last_synced_at": "2026-10-07T07:42:41.787Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02130817"
    }
  ]
}